Abstract
Dysglycemia as a pre-stage of diabetes mellitus and abdominal obesity are closely interrelated at multiple levels and by a whole array of complex mechanisms, many of which seem to have the potential of causing harm to large blood vessels, in particular to coronary and peripheral vascular segments. Both conditions are associated with elevated circulating concentrations of free fatty acids in conjunction with insulin resistance, oxidative stress, mitochondrial dysfunction, disordered nitric oxide release, and endothelial dysfunction. Oscillating glucose levels seem to be associated with the most of the injury burden to endothelial cells of large blood vessels and also generate some kind of metabolic memory. In addition, the multiple effects of insulin also on the regulation of the vasculature are shifted towards vasoconstriction and proliferation in the context of insulin resistance and the excessively high levels.
Keywords: Dysglycemia, diabetes mellitus, abdominal obesity, peripheral vascular disease, coronary heart disease
Current Vascular Pharmacology
Title:Dysglycemia and Abdominal Obesity
Volume: 10 Issue: 6
Author(s): Eberhard Standl
Affiliation:
Keywords: Dysglycemia, diabetes mellitus, abdominal obesity, peripheral vascular disease, coronary heart disease
Abstract: Dysglycemia as a pre-stage of diabetes mellitus and abdominal obesity are closely interrelated at multiple levels and by a whole array of complex mechanisms, many of which seem to have the potential of causing harm to large blood vessels, in particular to coronary and peripheral vascular segments. Both conditions are associated with elevated circulating concentrations of free fatty acids in conjunction with insulin resistance, oxidative stress, mitochondrial dysfunction, disordered nitric oxide release, and endothelial dysfunction. Oscillating glucose levels seem to be associated with the most of the injury burden to endothelial cells of large blood vessels and also generate some kind of metabolic memory. In addition, the multiple effects of insulin also on the regulation of the vasculature are shifted towards vasoconstriction and proliferation in the context of insulin resistance and the excessively high levels.
Export Options
About this article
Cite this article as:
Standl Eberhard, Dysglycemia and Abdominal Obesity, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520936
DOI https://dx.doi.org/10.2174/157016112803520936 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes
Current Diabetes Reviews Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation
Current Drug Safety Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Target Based Virtual Screening of New Leads Inhibitor against Bacterial Cell Division Protein FtsZ for the Discovery of Antibacterial Agents
Medicinal Chemistry Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets The Link between Insulin Resistance and Mobility Limitation in Older Persons
Current Pharmaceutical Design Lipoproteins and Diabetic Microvascular Complications
Current Pharmaceutical Design Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Recent Patents on Oral Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Ethnicity Considerations in Diagnosing Glucose Disorders
Current Diabetes Reviews Vascular Effects of Avocado Seed Glycosides during Diabetes-induced Endothelial Damage
Cardiovascular & Hematological Disorders-Drug Targets Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Analysis of Protein Glycation Products by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Current Medicinal Chemistry Gut Involvement in NOD Mouse Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rho-Kinase and RGS-Containing RhoGEFs as Molecular Targets for the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued) Current Therapeutic Strategy in the Nasal Delivery of Insulin: Recent Advances and Future Directions
Current Pharmaceutical Biotechnology